|
|
1435 N. Hayden Road
Scottsdale, AZ 85257 USA
phone:877-970-4970
fax:866-857-8792
|
|
| Symbol |
Private |
| Founded |
1997 |
| Employees |
55 |
|
|
| www.regenesisbiomedical.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Noninvasive regenerative medicine products |
|
| Management |
| Virginia S. Rybski, President and Chief Executive Officer; Dennis Genge, Vice-President and Chief Financial Officer; Richard A. Isenberg, M.D., Vice-President of Clinical and Regulatory Affairs; Scott Robey, Vice President, Marketing; Tom Eisiminger, Jr. Vice President, Sales |
| |
|
|
| |
|
| Keywords |
| provant therapy system, durable medical equipment, medicaid services, CMS, DME |
|
|
|
| Description |
|
Regenesis Biomedical Inc. is a privately held medical technology company focused
on developing and marketing noninvasive regenerative medicine products. Regenesis
developed, patented, and now markets the Provant Therapy System, that delivers pulsed
and modulated radio-frequency energy that triggers cellular rejuvenation and stimulates
healing and is indicated for the palliative treatment of post-operative pain and edema in
superficial soft tissue. Their customers include health care facilities and providers that
serve patients being treated by acute care hospitals, long-term acute care hospitals, skilled
nursing facilities, rehabilitation centers, home health care agencies, and wound care
clinics. |
|
| Products / Services |
Regenesis developed, patented, and now markets the Provant Therapy System.
|
|
| Technology / Differentiation |
| Pulsed and modulated radio frequency energy that triggers soft tissue cells to replicate and produce proteins |
|
| Market / Customers |
Their customers include health care facilities and providers that serve patients treated in acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home healthcare agencies, and wound care clinics as well as by patients in their homes under physician orders.
|
|
| Competitors / Substitutes / Alternatives |
Various companies provide products for Wound care but none are active similar to our technology.
|
|
| Strategy |
Obtain specific reimbursement for Medicare and Private Pay following a full random controlled clinical trial. Increase product lines in order to expand markets.
|
|
| Funding |
| Total capital raise to date is under $9MM. Currently seeking $11MM. |
|
| Status |
| FDA Cleared device with sales of approximately $11MM in 2009. Revenues are primarily through a government contract. Currently operating a cash break even, but seeking growth capital to greatly expand markets and reimbursement. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members